Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS), where inflammation, demyelination together with the axonopathy are the cardinal features on pathologic ground, with a combined genetic and environmental background. The associations of PD-1 single nucleotide polymorphisms (SNPs): PD-1.3 (in intron 4), PD-1.5 and PD-1.9 (both in exon 5) with clinical manifestation of MS in 479 south Polish individuals including 203 MS patients were analyzed. Presence of PD-1.5 T allele was linked with the first manifestations of disease: diplopia and pyramidal signs -favored pyramidal signs but protected against of diplopia development. Farther, PD-1.3G/PD-1.5C/PD-1.9C haplotype significantly favored whereas GTC protected against diplopia. Besides, GTT haplotype strongly favored non-severe RRMS outcome and ATC haplotype was specific only for these MS patients. Our population-based case-control study, investigating selected three PD-1 SNPs: PD-1.3, PD-1.5 and PD-1.9, revealed that polymorphic variation may be rather disease-modifying than MS risk factor.
Introduction
Multiple sclerosis (MS) is a chronic immune-mediated inflammatory disease of the central nervous system (CNS), where inflammation and demyelination of the white matter is a consequence of an autoimmune attack aimed at myelin sheath, with a highly heterogeneous course (Joller et al., 2012) . The most common form of the disease (≈ 85%) is a relapsing-remitting MS (RRMS) with episodes of acute worsening of function followed by partial or complete recovery (Lassmann, 1998; McKay et al., 2015) , and, within 20 years, approximately 50% will go on to develop secondary progressive MS (SPMS). SPMS defined as a steady clinical deterioration, and independent of relapses (McKay et al., 2015; Tremlett et al., 2009 ). Moreover, a higher female preponderance is consistently seen in relapsing-onset but not in progressive-onset of MS (Tremlett et al., 2009) .
The etiology of MS is not well understood but is likely a combination of both genetic and environmental factors. One hypothesis on the etiology of MS is that autoreactive T cells play an essential role in inducing tissue inflammation in MS. It has been proposed that autoreactive T cells are activated by chance in the peripheral immune compartment and transport to the CNS, where they get reactivated by self-antigen to induce inflammation and demyelination (Joller et al., 2012) . One of the controller of peripheral tolerance regulation, by inhibition the expansion of selfreactive T cells, is the PD-1 pathway, one of the immune checkpoint regulation pathway. The PD-1/PD-L1 interactions influence reactivation, expansion and effector function of autoreactive T cells in tissue, and what is important -loss of PD-1 on T cells compromises peripheral tolerance (Probst et al., 2005; Brown et al., 2003) .
In EAE PD-1 blockade causes an increase of autoreactive (MOG-specific) T cells frequencies, and DTH responses to the autoantigen, as well as greater autoantibody production, and disease severity, which altogether pointed PD-1 pathway as regulator of the autoimmune, MOGreactive T cells. Moreover, inhibitions apply not only to antigen specific T cell expansion, but also T cell activation and both Th1 and Th2 cytokines production. Altogether, this clearly indicates the PD-1 pathway as essential players in autoimmunity inhibition by regulating both central and peripheral tolerance.
Consequently, prevoiusly mentioned strong evidences clearly justify selection of PD-1 gene (PDCD1) as a candidate MS susceptibility gene. Instead of candidate gene and genome wide association studies, single-nucleotide polymorphisms (SNPs) in the PD-1 gene have demonstrated relevant associations with a higher risk of developing autoimmune diseases in certain ethnic groups (Lee et al., 2014) . In detail, observations from case-control association studies of polymorphic variation within PDCD1 and other autoimmune diseases, i.e. systemic lupus erythematosus (SLE) (Prokunina et al., 2002; Kristjansdottir et al., 2010; Lin et al., 2004; Ferreiros-Vidal et al., 2004; Sanghera et al., 2004; Thorburn et al., 2007; Velazquez-Cruz et al., 2007) , rheumatoid arthritis (RA) (Lin et al., 2004; Prokunina et al., 2004; Liu et al., 2014; Tahoori et al., 2011; Iwamoto et al., 2007; Kong et al., 2005) , type 1 diabetes (T1D) (Momin et al., 2009; Asad et al., 2007a; Ni et al., 2007; Nielsen et al., 2003; Asad et al., 2007b) , ankylosing spondylitis (AS) (Lee et al., 2006; Liu et al., 2011; Yang et al., 2015) , Graves' disease (GD) (Newby et al., 2007) , myasthenia gravis (MG) (Sakthivel et al., 2008) and neuromyelitis optica (NMO) (Asgari et al., 2012) pointed its connection with autoimmunity, which altogether may testify that the PD-1 gene is rather one of the good candidate overall autoimmune than disease-specific gene. In context of multiple sclerosis, no matter how a connection of the PDCD1 genetic variability was not being observed, a relationship between PDCD1 variability and MS phenotype -a primary progressive MS (PPMS) was observed (Kroner et al., 2005) .
Therefore we conducted a population-based case-control study to investigate the association of selected three SNPs within PDCD1: PD-1.3, PD-1.5 and PD-1.9 with MS as well as disease outcome.
Materials and methods

Study population
Patients characteristic
203 unrelated MS patients (129 (63.5%) female and 74 (36.5%) men), with clinically diagnosed MS according to the McDonald Criteria (McDonald et al., 2001 ) classification, were enrolled in this study. All patients were recruited since 1995 at the MS Clinic, Department of Neurology, Wroclaw Medical University, Poland. Medical documentation was available from the records of the MS Clinic. A neurological examination, together with an evaluation of severity using Kurtzke's expanded disability status score (EDSS) (Kurtzke, 1983) , was performed on the day on blood sampling for genetic studies.
The mean age (± standard deviation (s.d.)) of the MS patients examined at the time of blood sampling was 41.4 ± 10.4 years (range 20-74 years). The mean age at disease onset in MS group was 30.2 ± 7.4 years (mean ± s.d.) (range 16-50 years), and the mean duration of the disease (± s.d.) was 11.2 ± 7.2 years (1.0-34.0 years).
As a first symptom of disease, optic neuritis occurred in 45 (22.1%), diplopia in 42 (20.6%), ataxia/vertigo in 35 (17.2%), paresthesias in 29 (14.2%), pyramidal signs in 62 (30.4%), and vegetative signs in 2 (0.98%) patients.
Based on criteria considering the clinical course of the disease proposed by Lublin and Reingold (Lublin and Reingold, 1996) there were 123 (60.6%) MS patients with relapsing-remitting phenotype of disease (RRMS, 83 (67.5%) female and 40 (32.5%) male), while 80 (39.4%) patients developed secondary progressive MS (SPMS, 46 (57.5%) female and 34 (42.5%) male).
The mean duration of RRMS was 7.58 ± 4.95 years (mean ± s.d.) (range 1.0-27.0 years). Disease severity according to the EDSS scale ranged between 1.0 and 8.0 (mean ± s.d.: 4.20 ± 2.01) in all MS patients, in RRMS ranged between 1.0 and 6.0 (mean 2.9 ± 1.33 s.d.) and in SPMS ranged between 4.0 and 8.0 (mean 6.2 ± 0.99 s.d.).
The median value for interattack intervals (first two relapses) was 18 months. RRMS group of patients was divided according to severity of disease by meaning of duration between I and II relapse (the cut off was 2 × s.d., ≤ 60 months) to group of RRMS with severe (n = 107, 87.7%) and non-severe (n = 15, 12.3%) outcome.
The SPMS was defined when continual worsening of symptoms and signs was evident for a period of at least 6 months without superimposed relapses. This resulted in a change of score on the EDSS scale of at least 0.5 points. In the later observation, periods of stability could be recorded but disease was characterized by continuous progression. The median time of progression from the RRMS to the SPMS was 6 years.
Multiple Sclerosis Severity Score (MSSS) (Roxburgh et al., 2005 ) was determined for whole MS group, RRMS and SPMS subgroups and was 5.25 ± 2.26, 4.34 ± 2.04, 6.64 ± 1.82 (mean ± s.d.), respectively.
Control group
The control group consisted of 276 apparently healthy volunteers from the same geographical area (125 (45.3%) females and 151 (54.7%) males).
The local ethics committee approved the study protocol, and informed consent was obtained from each individual prior including into the study.
Ethical approvals
The local ethics committee approved the study protocol.
Genotyping of polymorphisms
Genomic DNA was isolated from whole frozen blood as described previously by Karabon et al. (Karabon et al., 2009 ).
The SNPs: PD-1.3 (rs11568821, c.627 + 189G N A, +7146G N A) located in intron 4, PD-1.5 (rs2227981, c.804 T N C, +7785C N T) and PD-1.9 (rs2227982, c.644C N T, +7625C N T) both located in exon 5 of the PDCD1 were examined by PCR-restriction fragment length polymorphism (PCR-RFLP) technique using PstI, PvuII, and DrDI enzymes (Fermentas, Burlington, Ontario, Canada) . The primers were designed according to the complete PDCD1 (NC_000002.12) sequence derived from the NCBI Sequence Viewer (http://www.ncbi.nlm.nih.gov/). The primer sequence and RFLP condition were listed in Table 1 .
Statistical analyses
The Hardy-Weinberg equilibrium (HWE) was tested separately for the studied groups by comparing observed and expected frequencies of genotypes using χ 2 analysis. Categorical data between MS patients and controls as well as between patients with different disease phenotypes were compared using the χ 2 test with appropriate correction: Yates' (when at least one cell value was not N 5) or Bonferroni multiple adjustments (in case of the multiple comparisons). Genotype and allele comparison was performed using the SHEsis software (http://analysis.bio-x.cn/myAnalysis.php) and Simple Interactive Statistical Analysis platform (SISA, http://www.quantitativeskills. com/sisa/). Haplotype and linkage disequilibrium (LD) coefficients were estimated using the SHEsis software.
Comparison of the descriptive continuous variables of age, age at disease onset, duration between I and II relapse, EDSS (expressed by means or medians) in context of MS outcome as well as PDCD1 polymorphic variation was done using one-way analysis of variance (ANOVA) and Tukey's test (post-hoc test) or the Mann-Whitney rank test (M-W test) depending on normality of distribution (tested using the Kolmogorov-Smirnov test).
The interattack interval and time to transition from the RRMS to the SPMS were estimated using the Kaplan-Meier method. The log rank test was used to compare the interattack interval and time to transition from the RRMS to the SPMS, and the F Cox test when comparison was made in the context of PDCD1 polymorphic variations.
The combined effects of genetic markers (PD-1.3, PD-1.5, and PD-1.9) and non-genetic factors (age [year] , gender and first symptom of disease analyzed as individual parameter: optic neuritis, diplopia, ataxia/vertigo, paresthesias, pyramidal signs) on the MS progression were analyzed by multivariate logistic regression analysis forward logistic regression analysis using the stepwise method in 191 MS patients with full genotyping results for all studied SNPs. With respect to clinical value of severity of first MS symptoms the presence of the cerebellar symptoms: pyramidal signs and/or ataxia/vertigo was classified as prone severe first MS symptoms (coded as 1 in stepwise multivariate logistic regression model), similarly as in the case of male gender (Probst et al., 2005) . Odds ratios (ORs) are presented with 95% confidence intervals (CI). The model was selected on the basis of goodness-of-fit criteria such as determination coefficient R 2 Cox-Snell and Akaike Information Criteria (AIC), where a greater R 2 and a lower AIC value was an indicator for a the best statistical fit. Goodness of fit of the regression model was assessed with the Hosmer and Lemeshow's test. All tests were performed with STATISTICA 10.0 software (StatSoft, Crakow, Poland). Differences were considered statistically significant if the p b 0.05.
Results
All PD-1 genotype distributions in the controls as well as in MS patients were consistent with those expected from the HWE model (all p N 0.05, Table 2 ).
PD-1 gene polymorphisms and MS risk
Univariate analysis did not show any association of studied PD-1 SNPs with the risk of MS. Neither dominant nor recessive models adopted to the analysis showed association with MS risk (Table 2) .
A strong LD between all studied PD-1 SNPs in MS patients: PD-1. Haplotype evaluation of all polymorphic sites did not show any impact on MS risk (Supplementary Table 1 ).
PD-1 gene polymorphisms and clinical data in MS
All selected PD-1 SNPs were subjected to analysis for correlations with clinical data regarding gender, age, age at disease onset, initial manifestation of disease (optic neuritis, ataxia and/or vertigo, diplopia, pyramidal signs, paresthesias), first interattack interval, transition into progression from the RRMS to the SPMS, and severity of disease by meaning of EDSS.
We found that PD-1.5 polymorphism correlated with the first manifestations of disease: diplopia and pyramidal signs (Table 3 ). In recessive model the presence of PD-1.5 T allele (TT + CT vs. CC) favored pyramidal signs development (p = 0.02, OR = 2.20, 95%CI:1.13-4.32), but protected against of diplopia as initial manifestation of MS (p = 0.008, OR = 0.40, 95%CI:0.20-0.80) ( Table 3) .
At the haplotype level association was preserved only in case of diplopia. PD-1.3G/PD-1.5C/PD-1.9C haplotype significantly favored whereas GTC haplotype protected against diplopia development as an initial MS manifestation (p = 0.03, OR = 1.74, 95%CI:1.04-2.89, and p = 0.02, OR = 0.54, 95%CI:0.32-0.93, respectively) ( Table 4) .
We did not find any association of studied SNPs with stage of MS (RRMS or SPMS) on univariate as well as on haplotype level (Table 2  and Supplementary Table 1 ). However, when we analyzed RRMS with regard to duration between I and II relapse, we observed an association at haplotype level. PD-1.3A/PD-1.5T/PD-1.9C haplotype was observed only in patients with non-severe (χ 2 = 11.42, p = 0.0007), and GTT strongly favored non-severe outcome of RRMS (χ 2 = 12.92, p = 0.0003, OR = 0.005, 95%CI:0.00-0.09) ( Table 5) . We did not found any connection of studied SNPs on age at disease onset as well as on transition into progression from the RRMS to the SPMS (data not showed).
A different genotype distribution at site PD-1.3 within control group with respect to gender (χ 2 = 10.03, p corrected = 0.01) was observed Table 2 PD-1.3 (rs11568821), PD-1.5 (rs2227981) and PD-1.9 (rs2227982) genotype and allele frequencies in patients with multiple sclerosis (MS) and in control group. Table 3) . Kaplan-Meier analysis showed no correlation of PD-1 gene polymorphisms with the first interattack interval as well as on time to transition from the RRMS to the SPMS (data not showed).
Logistic regression analysis showed that SPMS was associated with age, age at disease onset, and presence of cerebellar symptoms as first signs of MS (p = 0.0000, OR = 1.16, 95%CI:1.11-1.22, p = 0.0412, OR = 1.04, 95%CI:1.00-1.09, and p = 0.01, OR = 2.09, 95%CI:1.16-3.76, respectively) (Table 6 ). Farther, significant predictors of occurrence of SPMS results in the model were age, age at disease onset, and PD-1.5 marker. The increase of age (by 1 year) significantly increases the risk of MS progression of 33% (B = 0.29, p = 0.00, OR = 1.33, 95%CI:1.23-1.44), and each year of early occurrence of MS increases the risk of progression (B = − 0.21, p = 0.0000, OR = 0.814, 95%CI:0.75-0.89). Moreover, the presence of the PD-1.5 wild C allele over 3-fold increases risk of transition from RR to SPMS (p = 0.05, OR = 3.03, 95%CI:1.00-9.14) ( Table 6 ). The goodness of fit statistics (Hosmerand Lemeshow's test: p = 0.76) indicated a satisfactory fit for the model (Table 6 ).
Discussion
Programmed cell death-1 (PD-1, CD279), an inhibitory immunoreceptor expressed on T-, B-and myeloid cells, a member of B7/CD28 superfamily is mainly involved in T and B cells activation (Blank et al., 2005; Wang et al., 2009) . Accumulative evidence suggests that engagement of PD-1 by its ligands PDL-1 (B7-H1) or PDL-2 (B7-DC) inhibits T cell receptor-mediated proliferation and cytokine production in activated T lymphocytes (Bennett et al., 2003) . Consistent with its role in maintaining self-tolerance, PD-1 regulates T cell function only in suboptimal conditions of T cell receptor activation and CD28 costimulation (Bennett et al., 2003; Freeman et al., 2000) . The outcome of PD-1 activation is affected by factors such as cytokines (e.g., IL-6, IL-10), the level of co-stimulation, and TLR signaling (Bennett et al., 2003; Zhong et al., 2004) . Evidence from animal models of MS (EAE) strongly confirmed engagement of PD-1/PDL-1/2 pathway in MS pathogenesis (Chen et al., 2009; Cheng et al., 2007; Salama et al., 2003; Latchman et al., 2004; Carter et al., 2007) and altogether all these observations indicate the PD-1 molecule as potential important factor involved in the MS pathomechanism.
Since genetic variation may interfere with correct expression and/or function of encoded molecules (Prokunina et al., 2002; Kristjansdottir et al., 2010; Prokunina et al., 2004; McDonald et al., 2001; Blank et al., 2005; Daroszewski et al., 2009) , and several functional PDCD1 polymorphisms were described (Prokunina et al., 2002; Kristjansdottir et al., 2010; Prokunina et al., 2004; McDonald et al., 2001) , we assumed that the PDCD1 polymorphic variation may be a MS risk as well as prediction factors in a direct or indirect manner.
One of the selected polymorphism which impairs a PD-1 inhibitory effect and augments lymphocyte activity was the PD-1.3 (rs11568821, c.627 + 189G N A, + 7146G N A) SNP. Substitution of the guanine (G) to adenine (A) at nucleotide +7146 in the intron 4 at this polymorphic site throughout the disruption of the binding of runt-related transcription factor 1 (RUNX1, also called AML1) alters transcriptional regulation and PD-1 expression (Prokunina et al., 2002; Kristjansdottir et al., 2010; Prokunina et al., 2004) . From the autoimmune background, by reducing basal and induced PD-1 expression at early-to-intermediate stages of CD4+ T cell activation, PD-1-mediated inhibition of T cell proliferation and IFNγ production (in a dose-dependent manner) (Bertsias et al., 2009) , indirectly affects the levels of PD-1 after optimal stimulation (McDonald et al., 2001) . So, it has been hypothesized that aberrant regulation of PD-1 expression and function may be a results of combined direct (PD-1.3 SNP) and indirect (inflammatory milieu) effects (Bertsias et al., 2009) .
We included into research another two SNPs: a synonymous mutation -PD-1.5 (NP_005009.2: p.Ala268 =) and the missense -PD-1.9 causing the change in their synthesized amino acid at codon 215 (NP_005009.2: p.Ala215Val), both located within exon 5 of the PDCD1. Till now, no research explore functional consequences of those SNPs, however using in silico tools (https://snpinfo.niehs.nih.gov/snpinfo/ snpfunc.php) based on the methods described by Xu and Taylor (Xu and Taylor, 2009) we predicts that PD-1.9 alternative allele may affects splicing.
To date only two studies concerned an association of polymorphic variation within PD-1 gene and multiple sclerosis (Kroner et al., 2005 ; PD-1.5 (rs2227981) PD-1.9 (rs2227982) 1 -χ 2 = 1.14, df = 2, p = 0.56 6 -χ 2 = 7.28, df = 2, p = 0.03 11 -χ 2 = 0.18, df = 1, p = 0.67 2 -χ 2 = 0.67, df = 2, p = 0.72 7 -χ 2 = 2.68, df = 2, p = 0.26 12 -χ 2 = 1.18, df = 1, p = 0.28 3 -χ 2 = 2.45, df = 2, p = 0.29 8 -χ 2 = 5.67, df = 2, p = 0.06 13 -χ 2 = 0.47, df = 1, p = 0.49 4 -χ 2 = 0.63, df = 2, p = 0.73 9 -χ 2 = 0.95, df = 2, p = 0.62 14 -χ 2 = 1.39, df = 1, p = 0.24 5 -χ 2 = 0.07, df = 2, p = 0.97 10 -χ 2 = 0.07, df = 2, p = 0.97 15 -χ 2 = 1.55, df = 1, p = 0.21 McDonald et al., 2001 ), but one of them was on very small group of MS patients (n = 42). This made by Kroner et al. (Kroner et al., 2005) including 272 healthy donors and 939 MS patients, was weighted deviations from HWE in both groups (healthy donors: χ 2 = 10.23, p = 0.001, and MS patients: χ 2 = 74.70, p = 0.000000).
Since the Hardy-Weinberg model predicts equilibrium genotype proportions in the population assuming random matching, it is critical to fit HWE model in control group. The results obtained by Kroner et al. (Kroner et al., 2005) in German healthy person deviated significantly from HWE. The heterozygous GA allele combination (heterozygous genotype) was significantly over-represented: the obtained frequencies of GG, GA and AA genotypes were 58% (n = 157), 41% (n = 111) and 1% (n = 4), compared with a Hardy-Weinberg expectation of 61% (n = 166), 34.2% (n = 93), 4.8% (n = 13), respectively, based on the observed frequencies of A and G alleles. The more pronounced deviation was observed for overall patients as well as in clinically deviated subgroups, where in all cases an underrepresentation of mutated PD-1.3A allele was noted. Observed excess of homozygotes may be due to four factors: the locus is under selection, 'null alleles' may be present (in consequence -a false observation of excess homozygotes), inbreeding may be common in the population, and the presence of population substructure may lead to Wahlunds' effect, and an additional data i.e. demographic information are necessary to final explanation of such observations. Previous literature data have described a large variation in the frequencies of genotypes at PD-1.3 site among different ethnic groups (Prokunina et al., 2002; Thorburn et al., 2007) . 
Global result (frequency b 0.03 in all groups has been dropped).
Total diplopia "-" = 304.0, total diplopia "+" = 78.0, total paresthesias "-" = 328.0, total paresthesias "+" = 54.0, total pyramidal sign "-" = 262.0, total pyramidal sign "+" = 120.0, total ataxia/vertigo "-" = 322.0, total ataxia/vertigo "+" = 60.0, total optic neuritis "-" = 292.0, total optic neuritis"-" = 90.0. I:II: χ (Asgari et al., 2012) including 155 controls, the HWE model has been preserved (χ 2 = 0.82, p = 0.37).
However inconsistence in PD-1.3 genotype distribution between our and Kroner's studied groups were observed, in both cases PD-1.3 was not associated with MS risk. Similar observation was made by Asgari et al. (Asgari et al., 2012) . Altogether, this probably may indicated that PD-1.3 has no impact on disease susceptibility.
When the analysis was made in context of clinical outcome, this SNP was not associated with relapsing-remitting (RRMS) as well as secondary progressive (SPMS) phenotype of disease in our as well as Kroner's study (Kroner et al., 2005) . But, ultimately, they found that this SNP may acts as a genetic modifier for disease progression since they observed an over-distribution of A-allele in primary progressive MS patients (PPMS). We did not investigate a similar dependence in our research because of the lack of PPMS patients in our MS patients cohorts.
Moreover, neither this study nor Kroner's et al. (Kroner et al., 2005 ) study shows any connection between PD-1.3 and clinical data regarding gender, age at disease onset, initial manifestation of disease (optic neuritis, ataxia and/or vertigo, diplopia, pyramidal signs, paresthesia), first interattack interval and transition into progression from the RRMS to the SPMS, and severity of disease by meaning of EDSS.
Since our investigation concerned the association of three PD-1 SNPs: PD-1.3, PD-1.5, and PD-1.9, we then conducted a haplotype analysis in context of MS risk and disease outcome. Similar to results from univariate analysis, this approach also did not show any connection with MS risk. In turn, applied for the first time by our team new approach taking into account the severity of the RRMS (based on the time of duration between I and II relapse) pointed an exclusive presence of specific PD-1 haplotype containing PD-1.3 A variant: PD-1.3A/PD-1.5T/PD-1.9C in patients with non-severe outcome, which was in connection with the functional effects due to the presence of the polymor- When we investigate further, the univariate logistic regression analysis takes into consideration studied genetic altogether with nongenetic factors pointed cerebellar symptom, age, and age at disease onset as predictive factors of MS progression (defined as transition from RRMS to SPMS), but when we looking at modelled probability of SPMS (multivariate logistic regression) apart from age and age of disease onset, the genetic marker PD-1.5 was shown as statistically important risk factor, whereas the presence of cerebellar symptoms were turned out to be irrelevant. The presence of PD-1.5 wild variant increases the chance of transition from RRMS to SPMS.
Studied concerned SNPs located within exon 5 of PDCD1 gave inconsistent results (Lin et al., 2004; Iwamoto et al., 2007; Lee et al., 2006; Yang et al., 2015) . The PD-1.5 polymorphism was shown as risk marker of RA among Chinese people in Taiwan (Lin et al., 2004) , whereas the PD-1.9 was linked with ankylosing spondylitis in Koreans (Lee et al., 2006) .
In our study we did not find a correlation of those two SNPs with MS risk on univariate level, but we observed a connection of PD-1.5 with initial manifestation of disease: diplopia and pyramidal signs. Since the nucleotide variation of this SNP does not change the encoded amino acid, it still can be a useful genetic marker in linkage association studies to test whether the PD-1 gene plays a role in autoimmune disease, including multiple sclerosis. We also cannot exclude the possibility that another genuine MS-susceptibility gene located adjacent to the PD-1 gene in the same chromosome region can interact to each other and thus each has an effect on MS risk and/or outcome. PD-1 gene is located on chromosome 2q37.3 in close to other autoimmune-related region 2q33.3, where previously studied by us another immune-inhibitory gene is located (Thorburn et al., 2007) . In our previous study we found a connection of three CTLA-4 SNPs: c.49A N G (rs231775, +49A/ G), CT60 (rs3087243, g.*6230G N A) and Jo31 (rs11571302, g.*10223G N T) functional polymorphisms with the first manifestation of disease .
Our work focused only on the clinical aspect of the disease, taking into consideration correlations of the first clinical symptoms appeared during the clinically isolated syndrome with the clinical course but not the MRI results. We realized that the MRI results will be valuable but our limitation was a permanent access to this facility, especially since the patients recruitment at 1995. The MRI were performed at the beginning of the disease, but before 2013, when the Recommendation was implemented (Lublin et al., 2014) , the latter MRI was not done in regular increments. So, our MRI results were not comparable, and our evaluation of the activity of Multiple Sclerosis included only one clinical marker. Additionally, in our opinion it should be taken into consideration a gene-environment, gene-gene and between the different loci on the same chromosome interactions, which may affect individual susceptibility to MS and/or its outcome. However, our study only focused on a single locus on a single gene, we conducted a haplotype-based method to evaluate the haplotypic effects on MS and its outcome. In order to fully understand the mechanisms involved in the regulation of immune response, particularly its breaking, the simultaneous analysis of genegene interactions of genes engaged into this process is required.
Conclusion
We postulated that genetic variation within PD-1 gene, an essential players of regulation mainly in peripheral rather than in central tolerance (Asad et al., 2007b) , may be probably one of the significant immune-related factors in multiple sclerosis with a chronic immunemediated inflammatory milieu. Its final role in MS pathomechanism needs, however, further studies in the more numerous MS patients group in different populations.
